title: Treatment with antidepressants and lithium is associated with increased risk of treatment with antiparkinson drugs: a pharmacoepidemiological study.
abstract: OBJECTIVE
  To estimate the risk for persons treated with antidepressants or lithium of subsequent treatment with antiparkinson drugs (APD).
  
  
  METHODS
  The Danish national prescription database supplied data on all persons who received antidepressants, lithium, or antidiabetics (first control group). A second control group was included comprising persons from the general population. Outcome was purchase of APD and the study period was 1995 to 1999.
  
  
  RESULTS
  In total, 1 293 789 persons were included. The rate ratio of treatment with APD after treatment with antidepressants was 2.27 (95% CI 2.14 to 2.42) for men and 1.50 (95% CI 1.43 to 1.58) for women. Figures for lithium were almost identical.
  
  
  CONCLUSIONS
  Persons treated with antidepressants or lithium are at increased risk of subsequently treatment with APD, showing an association between anxiety/affective disorder and Parkinson's disease.
authors.affiliation: Department of Psychiatry, University Hospital of Copenhagen, Rigshospitalet, Blegdamsvej 9, DK 2100 Copenhagen, Denmark. mette.brandt@rh.dk
authors.forename: M
authors.initials: M
authors.lastname: Brandt-Christensen
authors.forename: K
authors.initials: K
authors.lastname: Kvist
authors.forename: F M
authors.initials: FM
authors.lastname: Nilsson
authors.forename: P K
authors.initials: PK
authors.lastname: Andersen
authors.forename: L V
authors.initials: LV
authors.lastname: Kessing
mesh_terms: D000928:Antidepressive Agents / Q000627:therapeutic use*; D018692:Antimanic Agents / Q000627:therapeutic use*; D000978:Antiparkinson Agents / Q000627:therapeutic use*; D001008:Anxiety Disorders / Q000150:complications; D016022:Case-Control Studies; D003718:Denmark / Q000453:epidemiology; D011307:Drug Prescriptions / Q000706:statistics & numerical data; D016021:Epidemiologic Studies; D005260:Female; D006801:Humans; D016651:Lithium Carbonate / Q000627:therapeutic use*; D008297:Male; D019964:Mood Disorders / Q000150:complications; D010300:Parkinson Disease / Q000188:drug therapy / Q000453:epidemiology* / Q000209:etiology / Q000503:physiopathology; D017891:Pharmacoepidemiology; D012307:Risk Factors
chemical_list: D000928:Antidepressive Agents; D018692:Antimanic Agents; D000978:Antiparkinson Agents; D016651:Lithium Carbonate